Literature DB >> 18690526

Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats.

Gregory W Konat1, Michal Kraszpulski, Isaac James, Han-Ting Zhang, Jame Abraham.   

Abstract

Although cognitive dysfunction manifested by severe memory and attention deficits has been reported in up to 70% of cancer patients undergoing chemotherapy, the mechanisms of this serious side effect have not been defined. In particular, it has not been decisively resolved whether the dysfunction is attributable to the chemotherapy or to the malignancy itself. In the present study we tested whether cognitive dysfunction can be induced in an experimental setting by the administration of commonly used chemotherapeutics to rats. Female 10 month old Sprague-Dawley rats were injected intraperitoneally with a combination of 2.5 mg/kg of adriamycin (ADR) and 25 mg/kg of cytoxan (CTX). A total of four doses were given at weekly intervals. The control group was treated with saline only. No mortality and no apparent morbidity were observed in either group. However, the chemotherapeutic treatment severely impaired memory function of rats as measured by a passive avoidance test. This memory deficiency was fully prevented by the administration of an antioxidant, N-acetyl cysteine (NAC) injected subcutaneously three times a week at 200 mg/kg in the course of chemotherapeutic treatment. These results indicate that chemotherapeutic agents alone, i.e., in the absence of malignancy, damage the brain resulting in memory dysfunction. Moreover, the results strongly indicate that the damaging effect is mediated by oxidative stress, as memory dysfunction is preventable by the co-administration of NAC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690526     DOI: 10.1007/s11011-008-9100-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  42 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin.

Authors:  J Goodman; P Hochstein
Journal:  Biochem Biophys Res Commun       Date:  1977-07-25       Impact factor: 3.575

3.  The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.

Authors:  Y J Hu; Y Chen; Y Q Zhang; M Z Zhou; X M Song; B Z Zhang; L Luo; P M Xu; Y N Zhao; Y B Zhao; G Cheng
Journal:  Biol Trace Elem Res       Date:  1997-03       Impact factor: 3.738

4.  Mechanism of the inhibition of calf thymus DNA polymerases alpha and beta by daunomycin and adriamycin.

Authors:  M Tanaka; S Yoshida
Journal:  J Biochem       Date:  1980-03       Impact factor: 3.387

Review 5.  Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.

Authors:  R D Olson; P S Mushlin
Journal:  FASEB J       Date:  1990-10       Impact factor: 5.191

6.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Christina A Meyers; Maher Albitar; Elihu Estey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

7.  Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients.

Authors:  M Erhola; P Kellokumpu-Lehtinen; T Metsä-Ketelä; K Alanko; M M Nieminen
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

8.  Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.

Authors:  O M Friedman; I Wodinsky; A Myles
Journal:  Cancer Treat Rep       Date:  1976-04

9.  Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation.

Authors:  M Dürken; J Agbenu; B Finckh; C Hübner; U Pichlmeier; W Zeller; K Winkler; A Zander; A Kohlschütter
Journal:  Bone Marrow Transplant       Date:  1995-05       Impact factor: 5.483

10.  Adriamycin-induced oxidative stress in rat central nervous system.

Authors:  D Julka; R Sandhir; K D Gill
Journal:  Biochem Mol Biol Int       Date:  1993-04
View more
  45 in total

Review 1.  Chemotherapy-related cognitive dysfunction.

Authors:  Jeffrey S Wefel; Sanne B Schagen
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

2.  Evaluation of multiple neurotoxic outcomes in cancer chemotherapy.

Authors:  Bernard Weiss
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 3.  Translational approaches to treatment-induced symptoms in cancer patients.

Authors:  Robert Dantzer; Mary W Meagher; Charles S Cleeland
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

4.  Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin Lymphoma - a commentary on report from Krull and colleagues.

Authors:  Natia Esiashvili; Mohammad Khan; Christopher Flowers
Journal:  Transl Pediatr       Date:  2013-01

Review 5.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

6.  Oxidized Low-Density Lipoprotein and the Incidence of Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema Determined From Fundus Photographs.

Authors:  Ronald Klein; Chelsea E Myers; Kristine E Lee; Andrew D Paterson; Karen J Cruickshanks; Michael Y Tsai; Ronald E Gangnon; Barbara E K Klein
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

Review 7.  Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment.

Authors:  Christine D Craig; Bradley J Monk; John H Farley; Dana M Chase
Journal:  Support Care Cancer       Date:  2013-11-10       Impact factor: 3.603

Review 8.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

9.  Tanshinone I enhances learning and memory, and ameliorates memory impairment in mice via the extracellular signal-regulated kinase signalling pathway.

Authors:  Dong Hyun Kim; Sunho Kim; Su Jin Jeon; Kun Ho Son; Seungjoo Lee; Byung Hoon Yoon; Jae Hoon Cheong; Kwang Ho Ko; Jong Hoon Ryu
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 10.  Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases.

Authors:  Da-Zhi Liu; Bradley P Ander; Frank R Sharp
Journal:  Neurobiol Dis       Date:  2009-11-24       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.